Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies
Clinical Chemistry · 2025
DOI: 10.1093/clinchem/hvae170 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Ian S Goldlust und 1 weiteren Autor:innen. Beteiligte Einrichtung: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States. Hauptthemen laut MEDLINE: Aneuploidy, Cell-Free Nucleic Acids, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background Prenatal cell-free DNA (cfDNA) screening is a success story of clinical genomics that has translated to and transformed obstetric care. It is a highly sensitive and specific method of screening for the most common fetal aneuploidies, including trisomies 13, 18, and 21. While primarily designed to detect fetal chromosomal abnormalities, the test also analyzes maternal cfDNA, which can complicate interpretation of results. Occasionally, abnormalities in cfDNA that do not align with fetal aneuploidy may indicate benign or malignant maternal disease states, presenting unique diagnostic challenges and opportunities. Content This review explores the methods and implications of incidental cancer detection through prenatal cfDNA screening. Early case reports noted instances in which abnormal cfDNA results, initially suggestive of fetal aneuploidies, led to post-pregnancy diagnoses of maternal cancers. Subsequent large retrospective studies have established significant correlations between atypical prenatal cfDNA results and undiagnosed maternal malignancies. Abnormal cfDNA profiles, particularly those indicating multiple aneuploidies, first require fetal diagnostic tests, such as amniocentesis. If the fetal studies are normal, further investigation into a maternal source should proceed. Clinical management of these findings may involve a multidisciplinary approach, incorporating advanced imaging techniques and genetic counseling to ensure timely and accurate maternal diagnoses. Summary The integration of genome-wide analysis and innovative bioinformatics tools into prenatal cfDNA screening has enhanced its ability to identify potential cancer cases. Developing standardized guidelines for reporting and managing incidental findings is crucial to optimizing patient outcomes and mitigating psychological impacts on expectant persons and their partners.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
- Prenatal Genomics and Therapy Section, Center for Precision Health Research, National Human Genome Institute, National Institutes of Health, Bethesda, MD, United States.
- Office of the Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States.
ORCID-Profile: Diana W Bianchi
Zitieren
APA
Goldlust, I. S., & Bianchi, D. W. (2025). Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae170
Vancouver
Goldlust IS, Bianchi DW. Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvae170
BibTeX
@article{Goldlust2025,
author = {Goldlust, Ian S and Bianchi, Diana W},
title = {Incidental Detection of Maternal Cancer Following Cell-Free DNA Screening for Fetal Aneuploidies},
journal = {Clinical Chemistry},
year = {2025},
doi = {10.1093/clinchem/hvae170}
}
EUVIMED